Treatment of infected wounds with the antimicrobial peptide D2A21

Journal of Trauma

Volumn 54, Issue 4, 2003, Pages 770-774

  Chalekson, Charles P ^a   Neumeister, Michael W ^a   Jaynes, Jesse ^b  

^a SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Demegen Inc   (United States)

Author keywords

Antimicrobial peptide; D2A21; Infected wounds; Sulfamylon

Indexed keywords

ANTIINFECTIVE AGENT; D2A21; MAFENIDE; PEPTIDE; PEPTIDE D2A21; SULFADIAZINE SILVER; THERMAZENE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL INFECTION; CONTROLLED STUDY; CREAM; DRUG EFFECT; DRUG SCREENING; GEL; INOCULATION; MALE; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RAT; RAT STRAIN; SKIN; SKIN DEFECT; SURVIVAL; TREATMENT INDICATION; TREATMENT OUTCOME; WOUND CARE; WOUND INFECTION;

ANIMALS; ANTI-BACTERIAL AGENTS; BURNS; CHI-SQUARE DISTRIBUTION; DISEASE MODELS, ANIMAL; MALE; PEPTIDES; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RATS; RATS, WISTAR; SURVIVAL ANALYSIS; WOUND INFECTION;

EID: 0038070520     PISSN: 00225282     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TA.0000047047.79701.6D     Document Type: Article

References (45)

1. Ganz T, Lehrer RI. Defensins. Pharmacol Ther. 1985; 66: 191-205.
2. Gundmundsson GH, Agerberth B. Neutrophil antibacterial peptides, multifunctional effector molecules in the mammalian immune system. J Immunol Methods. 1999; 232: 45-54.
3. Lehrer RI, Lichtenstein AK, Ganz T. Defensins: antimicrobial and cytotoxic peptides of mammalian cells. Annu Rev Immunol. 1993; 11: 105-28.
4. Nicolas P, Mor A. Peptides as weapons against microorganisms in the chemical defense system of vertebrates. Annu Rev Microbiol. 1995; 49: 277-304.
5. Kagan BL, Selsted ME, Ganz T, Lehrer RI. Antimicrobial defensin peptides from voltage-dependent ion-permeable channels in planar lipid bilayer membranes. Proc Natl Acad Sci U S A. 1990; 87: 210-214.
6. Fujii G, Selsted ME, Eisenberg D. Defensins promote fusion and lysis of negatively charged membranes. Protein Sci. 1993; 2: 1301-1312.
7. Sawyer JG, Martin NL, Hancock RE. Interaction of macrophage cationic proteins with the outer membrane of Pseudomonas aeruginosa. Infect Immun. 1988; 56: 693-698.
8. Daher KA, Selsted ME, Lehrer RI. Direct inactivation of viruses by human granulocyte defensins. J Virol. 1986; 60: 1068-1074.
9. Harder J, Bartels J, Christophers E, et al. A peptide antibiotic from human skin. Nature. 1997; 387: 861.
10. Lehrer RI, Daher K, Ganz T, et al. Direct inactivation of viruses by MCP-1 and MCP-2, natural peptide antibiotics from rabbit leukocytes. J Virol. 1985; 54: 467-472.
11. Ogata K, Linzer BA, Zuberi RI, et al. Activity of defensins from human neutrophilic granulocytes against Mycobacterium avium-Mycobacterium intracellulare. Infect Immun. 1992; 60: 4270-4275.
12. Segal GP, Lehrer RI, Selsted ME, et al. In vitro effect of phagocyte cationic peptides on Coccidioides immitis. J Infect Dis. 1985; 151: 890-894.
13. Selsted ME, Tang Y, Morris WL, et al. Purification, primary structures, and antibacterial activities of beta-defensins, a new family of antimicrobial peptides from bovine neutrophils. J Biol Chem. 1993; 268: 6641-6648.
14. Shi J, Zhang G, Wu H, et al. Porcine epithelial beta-defensin-1 is expressed in the dorsal tongue at antimicrobial concentrations. Infect Immun. 1999; 67: 3121-3127.
15. Takemura H, Kaku M, Kohno S, et al. Evaluation of susceptibility of gram-positive and -negative bacteria to human defensins by using radial diffusion assay. Antimicrob Agents Chemother. 1996; 40: 2280-2284.
16. Bals R, Wang X, Wu Z, et al. Human beta-defensin 2 is a salt-sensitive peptide antibiotic expressed in human lung. J Clin Invest. 1998; 102: 874-880.
17. Ganz T, Lehrer RI. Defensins. Pharmacol Ther. 1995; 66: 191-205.
18. Ganz T, Selsted ME, Lehrer RI. Defensins. Eur J Haematol. 1990; 44: 1-8.
19. Goldman MJ, Anderson GM, Stolzenberg ED, et al. Human B-defensin-1 is a salt-sensitive antibiotic in lung that is inactivated in cystic fibrosis. Cell. 1997; 88: 553-560.
20. Shimoda M, Ohki K, Shimamoto Y, et al. Morphology of defensin-treated Staphylococcus aureus. Infect Immun. 1995; 63: 2886-2891.
21. Soong LB, Ganz T, Ellison A, et al. Purification and characterization of defensins from cystic fibrosis sputum. Inflamm Res. 1997; 46: 98-102.
22. van Wetering S, Sterk PJ, Rabe KF, et al. Defensins: key players or bystanders in infection, injury, and repair in the lung? J Allergy Clin Immunol. 1999; 104: 1131-1138.
23. Zucht HD, Grabowsky J, Schrader M, et al. Human beta-defensin-1: a urinary peptide present in variant molecular forms and its putative functional implication. Eur J Med Res. 1998; 3: 315-323.
24. Chalekson CP, Neumeister MW, Jaynes J. Improvement in burn wound infection and survival with antimicrobial peptide D2A21. Plast Reconstr Surg. 2002; 109: 1338-1343.
25. Schwab U, Gilligan P, Jaynes J, et al. In vitro activities of designed antimicrobial peptides against multidrug resistant cystic fibrosis pathogens. Antimicrob Agents Chemother. 1999; 43: 1435-1440.
26. Bennett LL, Rosenblum RS, Perlov C, et al. An in vivo comparison of topical agents on wound repair. Plast Reconstr Surg. 2001; 108: 675-687.
27. Boyce ST, Supp AP, Swope VP, Warden GD. Topical Sulfamylon reduces engraftment of cultured skin substitutes on athymic mice. J Burn Care Rehabil. 1999; 20: 33-36.
28. Cooper ML, Boyce ST, Hansbrough JF, et al. Cytotoxicity to cultured human keratinocytes of topical antimicrobial agents. J Surg Res. 1990; 48: 190-195.
29. Fox CL. Silver sulfadiazine: a new topical therapy for Pseudomonas in burns. Arch Surg. 1968; 96: 184-188.
30. Geronemus RG, Mertz PM, Eaglstein WH. Wound healing: the effects of topical antimicrobial agents. Arch Dermatol. 1979; 115: 1311-1314.
31. Kjolseth D, Barker FJ, Anderson GL, et al. Comparison of the effects of commonly used wound agents on epithelialization and neovascularization. J Am Coll Surg. 1994; 179: 305-312.
32. Leitch IO, Kucukcelebi A, Robson MC. Inhibition of wound contraction by topical antimicrobials. Aust N Z J Surg. 1993; 63: 289-293.
33. Maggi SP, Soler PM, Smith PD, et al. The efficacy of 5% Sulfamylon solution for the treatment of contaminated explanted human meshed skin grafts. Burns. 1999; 25: 237-241.
34. Murphy RC, Kucan JO, Robson, Heggers JP. The effect of 5% mafenide acetate solution on bacterial control in infected rat burns. J Trauma. 1983;23:878-881.
35. Watcher MA, Wheeland RG. The role of topical agents in the healing of full-thickness wounds. J Dermatol Surg Oncol. 1989; 15: 1188-1195.
36. Gayle WE, Mayhall CG, Lamb VA, Apollo E, Haynes BW Jr. Resistant Enterobacter cloacae in a burn center: the ineffectiveness of silver sulfadiazine. J Trauma. 1978; 18: 317-323.
37. Rubin RJ, Harrington CA, Poon A, et al. The economic impact of Staphylococcus aureus infection in New York City hospitals. Emerg Infect Dis. [serial online] 1999 January-March 5(1). Available at: http://www.cdc.gov/ncidod/EI/eid.htm. Accessed October 24, 2001.
38. Gayle WE, Mayhall CG, Lamb VA, et al. Resistant Enterobacter cloacae in a burn center: the ineffectiveness of silver sulfadiazine. J Trauma. 1978; 18: 317-323.
39. Hoffmann S. Silver sulfadiazine: an antibacterial agent for topical use in burns—a review of the literature. Scand J Plast Reconstr Surg. 1984; 18: 119-126.
40. Smoot EC III, Kucan JO, Graham DR, Barenfanger JE. Susceptibility testing of topical antibacterials against methicillin-resistant Staphylococcus aureus. J Burn Care Rehabil. 1992; 13 (2 pt 1):198-202.
41. Rodgers GL, Mortensen JE, Fisher MC, Long SS. In vitro susceptibility testing of topical antimicrobial agents used in pediatric burn patients: comparison of two methods. J Burn Care Rehabil. 1997; 18: 406-410.
42. Kozol RA, Gillies C, Elgebaly SA. Effects of sodium hypochlorite (Dakin's solution) on cells of the wound module. Arch Surg. 1988; 123: 420-423.
43. Brennan SS, Leaper DJ. The effect of antiseptics on the healing wound: a study using the rabbit ear chamber. Br J Surg. 1985; 72: 780-782.
44. Lineaweaver W, Howard R, Soucy D, et al. Topical antimicrobial toxicity. Arch Surg. 1985; 120: 267-270.
45. Lineaweaver W, McMorris S, Soucy D, Howard R. Cellular and bacterial toxicities of topical antimicrobials. Plast Reconstr Surg. 1985; 75: 394-396.